On Wednesday, the FDA approved Merus N.V.’s (NASDAQ:MRUS) Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung ...

Shares of Merus N.V. (MRUS) rocketed 32% on Friday morning after the stock witnessed price target hikes on the heels of the company announcing positive data from one of its ongoing drug trials.

Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling Petosemtamab in 2L+ r/m HNSCC interim clinical ...

Merus said Tuesday that the combination of its experimental drug petosemtamab with the checkpoint inhibitor Keytruda shrank tumors in 62% of patients with head and neck cancer, according to an interim ...

Monday - Friday, 6:00 - 7:00 PM ET It's that time again! "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.

Biotech company Genmab announced Sept. 29 it entered into an agreement to acquire all shares of Merus. The all-cash transaction is worth approximately $8 billion. Genmab is an international ...

Merus N.V. (NASDAQ:MRUS) stock moved lower on Monday. The company announced a research collaboration and license agreement with Biohaven Ltd. (NYSE:BHVN). Here’s what you need to know. What To Know: ...

– Petosemtamab granted Fast Track Designation for the treatment of patients with recurrent or metastatic head & neck squamous cell carcinoma – Phase 3 trial of petosemtamab monotherapy in previously ...

- Based on the Company’s current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus’ operations into 2028 UTRECHT, The Netherlands and CAMBRIDGE, Mass., ...